stockrow
Friday 6 November 2026
Export QDEL’s income statement to Excel — free account
QuidelOrtho Corporation
QDEL Healthcare Medical Devices
QuidelOrtho Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, down 1.89% from fiscal 2024.
- Revenue
- −11.6%
- EPS
- +92.7%
- Free cash flow
- +120.7%
- Total debt
- +10.5%
Quarter to September 2026, against a year earlier
10.73
2.11
−16.43%
Follow QDEL
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.28 | 0.45 | 0.42 | 0.71 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
36.94 | (10.82) | (33.96) | 14.68 | |
P/B ratio |
0.41 | 0.67 | 0.61 | 1.01 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.35 | 1.48 | 1.38 | 1.62 | |
EV/EBITDA |
10.39 | 11.79 | 22.24 | 19.76 | |
EV/Operating CF |
442.40 | (69.31) | 555.78 | 41.98 | |
EV/FCF |
(29.54) | (18.73) | (22.95) | (52.95) | |
Quick Ratio |
0.51 | 0.48 | 0.52 | 0.61 | |
Current Ratio |
1.36 | 1.39 | 1.43 | 1.50 | |
Net Debt/EBITDA |
0.00 | 24.69 | 31.41 | 53.69 | |
Debt/Assets |
50.81% | 50.59% | 47.76% | 45.94% | |
Debt/Equity |
1.64 | 1.63 | 1.45 | 1.38 | |
Asset Turnover |
0.45 | 0.44 | 0.44 | 0.45 | |
Operating CF/Net income |
(0.36) | 1.19 | 0.36 | (1.01) | |
Capex/Depreciation |
0.00 | (0.19) | (0.30) | (0.40) | |
Interest Coverage |
(0.14) | (0.40) | (0.62) | (1.30) | |
Research and Development Expense of Revenue |
6.87% | 7.72% | 7.24% | 6.33% | |
Selling, General and Administrative Expense of Revenue |
29.52% | 30.07% | 32.16% | 26.87% | |
Intangible Assets out of Total Assets |
0.45 | 0.47 | 0.45 | 0.44 | |
Share Based Compensation of Revenue |
0.00% | 1.90% | 1.73% | 1.49% | |
Graham Net Nets |
(3.51) | (2.14) | (2.14) | (1.24) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(51.36%) | (87.96%) | (108.46%) | (58.33%) | |
Free Cash Flow Yield |
(16.34%) | (17.68%) | (14.26%) | (4.31%) | |
Revenue per Share |
9.01 | 9.24 | 9.09 | 10.67 | |
Operating CF per Share |
0.29 | (1.62) | (0.48) | 1.95 | |
Capex per Share |
0.00 | (0.37) | (0.50) | (0.67) | |
Free Cash Flow per Share |
0.29 | (1.99) | (0.98) | 1.28 | |
Cash per Share |
2.42 | 1.81 | 2.06 | 2.50 | |
Shareholders Equity per Share |
26.07 | 25.99 | 27.15 | 28.33 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
26.07 | 25.99 | 27.15 | 28.33 | |
Free Cash Flow |
19.60 | (136.10) | (67.00) | 86.60 | |
Working Capital |
378.90 | 383.20 | 414.60 | 481.20 | |
Capital Expenditures |
(21.00) | (25.50) | (34.00) | (45.30) | |
Net Current Asset Value |
(2,544.00) | (2,563.80) | (2,400.30) | (2,401.50) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.04 | 0.05 | 0.06 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
381.00 | 313.50 | 322.95 | 349.70 | |
Average Payables |
233.50 | 227.65 | 237.20 | 262.70 | |
Average Inventory |
628.25 | 598.80 | 587.35 | 555.65 | |
Average Assets |
5,728.20 | 6,047.20 | 6,045.15 | 6,096.45 | |
Average Common Equity |
1,913.85 | 2,283.80 | 2,424.30 | 2,452.50 |
Columns are period end dates · fundamentals updated 5 Nov 2026